Literature DB >> 2912150

Cholecystokinin in pig plasma: release of components devoid of a bioactive COOH-terminus.

P Cantor1, J F Rehfeld.   

Abstract

Using radioimmunoassays specific for different sequences of cholecystokinin (CCK), we studied the intestinal release of CCK in pigs. After stimulation by intraduodenal infusion of HCl, plasma CCK concentrations, measured with an antiserum specific for the sulfated, bioactive sequence of CCK, increased from 1.4 +/- 0.7 to 42.7 +/- 11.7 pM in portal plasma and from 0.5 +/- 0.3 to 12.3 +/- 1.5 pM in peripheral plasma. The concentrations measured with an antiserum specific for the NH2-terminal sequence 5-10 of CCK-33 were considerably higher, increasing from 64 +/- 17 to 139 +/- 14 pM in portal plasma and from 69 +/- 7 to 102 +/- 9 pM in peripheral plasma. Chromatography suggested that the NH2-terminal immunoreactivity consisted of large CCK fragments devoid of the bioactive COOH-terminal octapeptide, i.e., desocta and/or desnona CCK-58, CCK-39, and CCK-33. The bioactive forms in both portal and peripheral plasma comprised CCK-58-, CCK-33-, CCK-22-, CCK-12-, and CCK-8-like forms. Generally, the CCK-22-like component predominanated, but although CCK-8 was more abundant than CCK-33 in portal plasma, these forms occurred in equal amounts in peripheral plasma. Large amounts of NH2-terminal immunoreactivity were also found in the venous effluent of the isolated perfused duodenum after stimulation with gastrin-releasing peptide; the venous perfusate contained mainly CCK-22- and CCK-8-like material, which together constituted greater than 80% of the bioactive CCK components. Both duodenal and jejunal mucosa contained components resembling NH2-terminal fragments as well as large amounts of intact CCK-58 and CCK-33.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912150     DOI: 10.1152/ajpgi.1989.256.1.G53

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  Role of gastrointestinal hormones in feeding behavior and obesity treatment.

Authors:  Timothy Sean Kairupan; Haruka Amitani; Kai-Chun Cheng; Joshua Runtuwene; Akihiro Asakawa; Akio Inui
Journal:  J Gastroenterol       Date:  2015-09-07       Impact factor: 7.527

Review 2.  The endoproteolytic maturation of progastrin and procholecystokinin.

Authors:  Jens F Rehfeld
Journal:  J Mol Med (Berl)       Date:  2006-05-06       Impact factor: 4.599

3.  Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.

Authors:  N Irwin; P Frizelle; I A Montgomery; R C Moffett; F P M O'Harte; P R Flatt
Journal:  Diabetologia       Date:  2012-07-20       Impact factor: 10.122

4.  Cardiomyocyte expression and cell-specific processing of procholecystokinin.

Authors:  Jens P Goetze; Anders H Johnsen; Caroline Kistorp; Finn Gustafsson; Camilla B Johnbeck; Jens F Rehfeld
Journal:  J Biol Chem       Date:  2015-01-27       Impact factor: 5.157

5.  Systemic cholecystokinin amplifies vago-vagal reflex responses recorded in vagal motor neurones.

Authors:  Edouard Viard; Richard C Rogers; Gerlinda E Hermann
Journal:  J Physiol       Date:  2011-12-12       Impact factor: 5.182

Review 6.  Overview of exocrine pancreatic pathobiology.

Authors:  Arun R Pandiri
Journal:  Toxicol Pathol       Date:  2013-11-03       Impact factor: 1.902

7.  Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats.

Authors:  K Miyasaka; A Funakoshi; A Jimi; R Nakamura; M Matsumoto; K Kitani
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

8.  Different downstream signalling of CCK1 receptors regulates distinct functions of CCK in pancreatic beta cells.

Authors:  Shang-lei Ning; Wen-shuai Zheng; Jing Su; Nan Liang; Hui Li; Dao-lai Zhang; Chun-hua Liu; Jun-hong Dong; Zheng-kui Zhang; Min Cui; Qiao-Xia Hu; Chao-chao Chen; Chang-hong Liu; Chuan Wang; Qi Pang; Yu-xin Chen; Xiao Yu; Jin-peng Sun
Journal:  Br J Pharmacol       Date:  2015-10-23       Impact factor: 8.739

9.  Mechanisms of action of CCK to activate central vagal afferent terminals.

Authors:  Richard C Rogers; Gerlinda E Hermann
Journal:  Peptides       Date:  2008-07-04       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.